Navigation Links
Belinostat in Medical News

CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA

- Conference call to be hosted on Tuesday, December 11th at 9:00 a.m. Eastern time - - Encouraging clinical results presented at ASH from the ongoing Phase II trial in T-cell lymphomas - - Positive End-of-Phase II meeting held with the FDA for b...

CuraGen Corporation Regains NASDAQ Listing Compliance

...in late January, we have successfully advanced our lead clinical program CR011-vcMMAE into Phase II development, completed the sale of our interest in belinostat for approximately $38 million in cash thus far, removed $50.9 million in debt from our balance sheet, and announced a reduction in our burn rate guida...

CuraGen Sells 5 Million TopoTarget Shares for Approximately $12 Million

...of CuraGen Corporation. "We also retain further potential upside related to belinostat consisting of up to $6 million in potential milestone payments on future ne...raGen's potential economic benefits from future net sales and sublicense of belinostat may constitute forward-looking statements within the meaning of the Private...

CuraGen Reports Third Quarter 2007 Financial Results

...CR-NCI-EORTC International Conference. These results, along with additional belinostat data being reported in December at the 2007 ASH Annual Meeting, will allow ...company developing diverse approaches for the treatment of cancer including belinostat and CR011-vcMMAE. By leveraging drug development strengths cultivated over ...

CuraGen to Present at the Bear Stearns 20th Annual Healthcare Conference

...or the treatment of cancer and for cancer supportive care. CuraGen is currently conducting clinical trials to investigate the potential of velafermin, belinostat and CR011-vcMMAE. By leveraging the drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promis...
Belinostat in Medical Technology

CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting

BRANFORD, Conn., Nov. 26 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ), a clinical-stage biopharmaceutical company focused on oncology, and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today that updated preliminary clinical trial results from the Phase II study ...

CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference

- Significant anti-tumor activity of combination IV belinostat in ovarian cancer reported - - Oral belinostat demonstrated to be safe and well-tolerated in Phase I - - Presentation of results from two NCI-sponsored clinical trials - - CuraGen to provide a clinical up...

CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia

BRANFORD, Conn., Aug. 28 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ) and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today the initiation of patient dosing in a Phase I/II clinical trial evaluating belinostat (PXD101), a histone deacetylase (HDAC) inhibitor, i...

CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs

- Enrollment completed in Phase II trial evaluating a single dose of velafermin for the prevention of severe oral mucositis - - Continued focus to define registrational path for belinostat in the treatment of cancer - - Conference call and webcast to be held ...

CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting

BRANFORD, Conn., April 12, 2007 /PRNewswire-FirstCall/ -- CuraGen Corporation announced today that new preclinical data on belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, and velafermin, a protein being investigated for the prevention of ...

CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE

...0.67 per share, during the same period in 2007. Significant one time transactions during the second quarter of 2008 included the sale of the rights to belinostat to TopoTarget A/S for approximately $38 million in cash and the repurchase of $50.9 million of debt for $43.2 million in privately negotiated transact...

CuraGen Advances CR011-vcMMAE into Phase II

...rporation (Nasdaq: CRGN ) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer including belinostat and CR011-vcMMAE. By leveraging drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising ...

CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma

...he four posters discussing Phase I and Phase II clinical trial results with belinostat being presented at the AACR-NCI-EORTC International Conference. Conference...company developing diverse approaches for the treatment of cancer including belinostat and CR011-vcMMAE. By leveraging drug development strengths cultivated over ...

CuraGen Announces Top-Line Phase II Results on Velafermin

...tics, October 22-26, 2007, in San Francisco, CA: belinostat Title: Phase II Multicenter Trial of belinostat (PXD101) in Combination with Carb...c Agents Title: A Phase I Study of Oral belinostat (PXD101) in Patients with Advance...

CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings

...sentation discussing interim clinical results with belinostat will be made at the 2007 American Society of Clini...nd anti-cancer activity of IV-administered belinostat (PXD101) plus carboplatin (C) or paclitaxe...mailto:info@curagen.com">info@curagen.com About belinostat ...
Belinostat in Biological News

Massey researchers induce cell death in leukemia

... bortezomib and romidepsin (Gloucester Pharmaceuticals) and bortezomib with belinostat (aka PXD101 from CuraGen Corporation and TopoTarget A/S), were examined in ...ly with both agents to induce cell death in human CLL cells. Romidepsin and belinostat are histone deacetylase (HDAC) inhibitors. "To the best of our knowle...
Belinostat in Biological Technology

Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL

Update on the Regulatory Strategy for Belinostat in PTCL COPENHAGEN, Denmark, September 5 /PRNewswire-FirstCall/ -- TopoTarget A/S (OMX: TOPO) announced that a positive reply from the FDA was received on a Special Protocol Assessment (SPA) for a phase III trial for belinostat in PTCL (...

CuraGen Sells Ownership of Belinostat to TopoTarget A/S

- CuraGen to receive approximately $45 million in cash, stock and future milestone payments - - Provides updated financial guidance for 2008 - - Conference call to be hosted today at 9:00 a.m. EDT - BRANFORD, Conn., April 22 /PRNewswire-FirstCall/ -- ...

CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma

BRANFORD, Conn., Dec. 19 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ), a clinical-stage biopharmaceutical company focused on oncology, and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today the initiation of patient dosing in a Phase II open-label, multi-center ...

TopoTarget Successfully Buys Back Full Control of Belinostat

Consolidates the Global Rights for the Product TopoTarget Successfully Buys Back Full Control of Belinostat, Consolidating the Global Rights for the Product TopoTarget Acquires US & RoW Rights From CuraGen Corporation COPENHAGEN, April 22 /PRNewswire/ -- -...

CuraGen Reports Third Quarter 2008 Financial Results

...50 per share, for the same period in 2007. Net income for the nine months ended September 30, 2008 and 2007 was primarily due to a gain of the sale of belinostat and a gain on the extinguishment of debt in the second quarter of 2008, and the sale of 454 Life Sciences Corporation in the second quarter of 2007. ...

CuraGen Reports Fourth Quarter and Year End 2007 Financial Results

...n excellent position to advance our core products, belinostat and CR011-vcMMAE, toward registrational developmen...d quarter of 2008; -- Updated Phase II results of belinostat in combination with carboplatin and paclitaxel...8; and -- Initiate Phase III trial of intravenous belinostat for the treatment of peripheral T-cell lymphom...

CuraGen Appoints Clinical Oncologist as VP of Medical Development

...or the treatment of cancer and for cancer supportive care. CuraGen is currently conducting clinical trials to investigate the potential of velafermin, belinostat and CR011-vcMMAE. By leveraging the drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promis...

CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer

...w on three oncology programs including velafermin, belinostat and CR011-vcMMAE. "Tim has done an outstanding jo... Phase II results from an ongoing trial evaluating belinostat in combination with carboplatin and paclitaxel... October from an ongoing trial evaluating oral belinostat for the treatment of advanced solid tumors at ...
Other Tags
(Date:7/31/2015)... ... ... Girl Scouts of Historic Georgia and Peach State Health Plan are teaming ... Friend First" program. Representatives from Peach State Health Plan presented a $10,000 check for ... our parent company, Centene Corporation, are dedicated to raising anti-bullying awareness. We are very ...
(Date:7/31/2015)... , ... July 31, 2015 , ... The 2015 ALS ... Major League Baseball and the Boston Red Sox honor Ice Bucket co-founders Pat Quinn ... MLB is donating $100,000 to further collaborative efforts among the ALS organizations to find ...
(Date:7/31/2015)... Toledo, Ohio (PRWEB) , ... July 31, 2015 ... ... U.S. District Court for the Northern District of Ohio, Western Division (Case No. ... complaint (Case No: 3:15-cv-00397), the women experienced spontaneous migration of their Implanon® implants, ...
(Date:7/31/2015)... NY and Rockport, ME (PRWEB) , ... July 31, 2015 , ... The alarm was ... op. , Glancing out of the window, he recalled that his equipment was set ... Chrystie Street tower, he jumped out of bed. , The photo speaks for itself. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Patients with higher levels ... a study published today in Nature Communications and led by researchers from the Icahn ... that variations in the gene RTN1 led to greater production of the related RNT1 ...
Breaking Medicine News(10 mins):Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 4Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3
(Date:7/8/2015)... NEW YORK , July 8, 2015 ... cancer globally, and the fourth most fatal, with a ... year. The poor prognosis of pancreatic cancer patients has ... to treatment, which is not being met by the ... contains an array of products with varying molecule types ...
(Date:7/7/2015)... 2015 Research and ... of the "Capacitive Fingerprint Sensors Patent Landscape" ... this date, fingerprint sensing technology is the most ... are well developed. This patent landscape focuses on ... The domain of capacitive fingerprint sensors is closely ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) ... Biometrics Market by Application, Technology, Function & Geography - ... The next generation biometrics market is expected ... of 17.9% between 2015 and 2020 Travel ... Safran SA ( France ), ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
Other Contents